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Unusual forms of pulmonary hypertension include pulmonary hypertension related to
mediastinal fibrosis and the use of serotonergic drugs. Here, we describe a patient with
diffuse mediastinal fibrosis and pulmonary hypertension while she was on dopamine
agonist therapy. A young woman, who was treated with cabergoline and bromocriptine
for hyperprolactinemia, presented with progressive dyspnea over several months.
Based on the clinical investigation results, in particular, elevated pulmonary arterial
pressures and significant perfusion defects on computed tomography (CT) pulmonary
angiography and ventilation/perfusion (V/Q) scintigraphy, chronic thromboembolic
pulmonary hypertension (CTEPH) was initially considered the most plausible diagnosis.
However, during an attempted pulmonary endarterectomy, loose fibrous tissues were
observed in the mediastinum and cryosection of the right pulmonary artery showed
fibrosis and chronic inflammation. Subsequent investigations revealed that diffuse
mediastinal fibrosis with concurrent pulmonary hypertension, and not CTEPH, was
the most likely diagnosis and cabergoline and bromocriptine may have triggered the
fibrotic changes. Both drugs are ergot-derived dopamine agonists, which are known
to cause cardiac valve fibrosis and less frequently, non-cardiac fibrotic changes. The
underlying mechanism is attributed to their interactions with serotonin receptors. There
is much evidence that serotonin, a potent vasoconstrictor and mitogen, is involved in
the pathogenesis of pulmonary hypertension. In conclusion, as CT and V/Q scintigraphy
findings can occasionally be deceptive, physicians should be particularly aware of
differential diagnoses in patients without obvious history of venous thromboembolism
that are suspected of having chronic thromboembolic pulmonary hypertension.
Keywords: dopamine agonist, serotonin, pulmonary hypertension, mediastinal fibrosis, adverse drug reaction
Abbreviations: CI, cardiac index; CT, computed tomography; CTEPH, chronic thromboembolic pulmonary hypertension;
CTPA, CT pulmonary angiography; DSA, digital subtraction angiography; EBUS, endobronchial ultrasound; FDG,
fluorodeoxyglucose; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; HRCT, high resolution
CT; IVC, inferior vena cava; MUM1, myeloma oncogene 1; NT-proBNP, terminal pro-B-type natriuretic peptide; PAPm,
mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PET, positive emission tomography; PVR,
pulmonary vascular resistance; TAPSE, tricuspid annular plane systolic excursion; V/Q, ventilation/perfusion.
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INTRODUCTION
Pulmonary hypertension, defined as an increase in resting
mean pulmonary arterial pressure (≥ 25 mmHg) as assessed
by right heart catheterization, is a serious condition that
can lead to right heart failure (Galie et al., 2016). Several
forms of pulmonary hypertension exist, including chronic
thromboembolic pulmonary hypertension (CTEPH), which is
caused by obstruction of the large pulmonary arteries typically
following an episode or recurrent episodes of pulmonary
embolism. The treatment of choice for CTEPH is pulmonary
endarterectomy, which is potentially curative (Jamieson et al.,
2003). It is therefore imperative to identify patients that are
eligible for surgery.
Other unusual forms of pulmonary hypertension include
pulmonary hypertension related to mediastinal fibrosis (Seferian
et al., 2015) and the use of serotonergic drugs (Seferian et al.,
2013). Mediastinal fibrosis (fibrosing mediastinitis) is a rare
condition characterized by proliferation of fibrous tissues in the
mediastinum often associated with granulomatous diseases, such
as histoplasmosis, tuberculosis and sarcoidosis and other fibro-
inflammatory and autoimmune diseases (Rossi et al., 2016). It
can be induced iatrogenically in relation to previous mediastinal
irradiation and treatment with methysergide maleate (Graham
et al., 1966), an ergot-derived serotonin antagonists previously
used in the treatment of migraine. Mediastinal fibrosis can cause
compression and obliteration of vital mediastinal structures,
i.e., the airways, esophagus and great vessels (Sherrick et al.,
1994). Thin-walled vessels with low intraluminal pressure, such
as superior vena cava and less frequently, the pulmonary arteries,
are especially subjected to compression by mediastinal masses
resulting in increased intravascular pressure. Due to its extended
course through the mediastinum, the right pulmonary artery is
more susceptible to mediastinal processes compared to the left
pulmonary artery.
Serotonin is a potent vasoconstrictor and mitogen that causes
smooth muscle cell hyperplasia and hypertrophy. There is much
evidence that it is involved in the pathogenesis of pulmonary
hypertension (Egermayer et al., 1999). In addition, an association
between the appetite suppressants, fenfluramine derivatives,
and pulmonary hypertension is well-established. Fenfluramine
derivatives cause increased serotonin levels by acting as
serotonin uptake inhibitors and induce transport-mediated
serotonin release (Seferian et al., 2013). However, whether other
serotonergic drugs, such as ergot-derived dopamine agonists,
are associated with an increased risk of developing pulmonary
hypertension remains unclear. Here, we describe a patient on
ergot-derived dopamine agonist therapy for hyperprolactinemia
that had diffuse mediastinal fibrosis and pulmonary hypertension
mimicking CTEPH.
CASE PRESENTATION
A 36-year-old woman, who presented with progressive exertional
dyspnea over 6 months, was referred to us as a potential
candidate for pulmonary endarterectomy with a presumptive
diagnosis of CTEPH, for which she was receiving anticoagulation
treatment. She did not report any chest pain or episodes of
syncope. She was diagnosed with a microprolactinoma after
experiencing galactorrhoea 7 years earlier, for which she received
low-dose cabergoline treatment (0.5 mg/week) for a year before
switching to bromocriptine (2.5 mg/day) when she wished to
become pregnant. She took bromocriptine for a year until she
became pregnant and the treatment was paused. Shortly after a
non-problematic pregnancy and childbirth, low-dose cabergoline
treatment (0.5 mg/week) was resumed. In total, the patient had
received ∼160 mg cabergoline and ∼900 mg bromocriptine and
her prolactin level remained within normal range on treatment.
She was a non-smoker and was on birth control pills for several
years. The medical history on the father’s side was unknown and
there was nothing remarkable on the mother’s side.
Clinical examination of the patient revealed a systolic murmur
and reduced breath sound in the right lung. The 6-min-
walk-distance was reduced to 259 m. An electrocardiogram
showed T-wave inversion in leads V3 and V4. Creatine kinase
MB isoenzyme and troponin T levels were within normal
range. However, the level of the NT-proBNP was elevated
to 2899 ng/L. Transthoracic echocardiography revealed a
moderately dilated right ventricle with impaired function and
moderate tricuspid regurgitation with a gradient of 92 mmHg.
Subsequent right heart catheterization showed severe pre-
capillary pulmonary hypertension with a mean pulmonary
arterial pressure of 52 mmHg and pulmonary vascular resistance
of 880 dyn.s/cm5 (a summary of main findings are listed
in Table 1). HRCT showed significantly thickened left and
right pulmonary arteries, elevated right hemidiaphragm and
non-specific infiltrates in the right lower lung. There was
no evidence of mediastinal lymphadenopathy. CT pulmonary
angiography revealed near-complete occlusion of the right
pulmonary artery and severe, short-segment stenosis as well as
wall irregularities in the left lobar and segmental pulmonary
arteries. Similar findings were observed during digital subtraction
angiography (Figure 1). PET-CT did not show any pathological
FDG-uptake. V/Q scintigraphy revealed absent perfusion to the
right lung that was not matched to the ventilation and several
segmental and sub-segmental mismatched perfusion defects in
the left lung. Spirometry showed reduced lung function of a
restrictive pattern. Biochemical and serological screening for
thrombophilia, autoimmune diseases and systemic connective
tissue diseases were all negative. Based on results from the above-
mentioned investigations, CTEPH as a consequence of previous
subclinical pulmonary embolism was initially considered the
most plausible diagnosis.
Pulmonary endarterectomy was attempted 7 months later,
during which, loose fibrous tissues were observed around
the aorta, main pulmonary artery and superior vena cava.
The right pulmonary artery appeared stiff and cryosection
of the artery showed fibrosis and chronic inflammation. In
light of the new findings, which were not compatible with
CTEPH, pulmonary endarterectomy was aborted. Cabergoline
treatment was discontinued immediately after the attempted
endarterectomy as it was suspected to have caused the fibrotic
changes and anticoagulation therapy was discontinued a few
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TABLE 1 | Summary of main findings.
Vital signs Heart rate: 97 min−1, blood pressure: 125/80 mmHg, temperature: 37.6◦C, saturation: 95%
6-min walk distance 259 m
Electrocardiography Sinus rhythm, T-wave inversion in V3 and V4
Transthoracic echocardiography Normal sized left atrium, normal left ventricular dimensions and function, moderately dilated right atrium and ventricle, TAPSE:
1.4 cm, -moderate tricuspid regurgitation with a gradient of 92 mmHg, dilated IVC with absent respiratory variation
Right heart catheterization CI (thermodilution): 1.8 L/min/m2, right atrial pressure: 19 mmHg, PAPm: 52 mmHg, PAWP: 13 mmHg, PVR: 880 dyn.s/cm5
Coronary angiography Normal
HRCT Thickened pulmonary arteries, elevated right hemidiaphragm, nonspecific infiltrates in the right lower lung
PET-CT No pathological FDG-uptake
CTPA and DSA See Figure 1
V/Q scintigraphy Absent perfusion to the right lung, segmental and sub-segmental mismatched perfusion defects in the left lung
Spirometry FEV1: 1.36 (42% predicted), FVC: 1.79 (48% predicted), FEV1/FVC: 76%
Histology See Figure 2
Bronchoscopy with EBUS No evidence of malignant cells or granulomatous inflammation in the endobronchial biopsy, bronchoalveolar lavage fluid and
transbronchial needle aspiration biopsy from lower paratracheal and subcarinal lymph nodes.
Blood test Normal blood count, normal liver and kidney function tests, C-reactive protein: 26 mg/L, erythrocyte sedimentation rate: 14 mm/hr,
prolactin: 288 mIU/L (on cabergoline treatment), NT-proBNP: 2899 ng/L, troponin-T: below limit of detection, negative screening for
thrombophilia, autoimmune and connective tissue diseases
Bronchoscopy results were obtained after the attempted pulmonary endarterectomy, while the rest of the results were obtained prior to or during the procedure. CI, cardiac
index; CT, computed tomography; CTPA, CT pulmonary angiography; DSA, digital subtraction angiography; EBUS, endobronchial ultrasound; FDG, fluorodeoxyglucose;
FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; HRCT, high resolution CT; IVC, inferior vena cava; NT-proBNP, terminal pro-B-type natriuretic
peptide; PAPm, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vascular resistance; PET, positive emission tomography;
TAPSE, tricuspid annular plane systolic excursion; V/Q, ventilation/perfusion.
days later. Histologic examination of the right pulmonary
artery biopsy (Figure 2) confirmed the cryosection results.
Immunohistochemical screening for overexpression of MUM1,
a lymphocyte-specific transcription factor associated with
a wide range of hematolymphoid neoplasms (Natkunam
et al., 2001), and IgG4, which can be associated with
idiopathic fibro-inflammatory disorders (Rossi et al., 2016), were
negative. Subsequent bronchoscopy showed no endobronchial
abnormalities. Endobronchial biopsy and transbronchial needle
aspiration biopsy showed nonspecific changes with no evidence
of malignancy or granulomatous inflammation. Repeat HRCT
showed pleural thickening and no evidence of retroperitoneal
fibrosis. Repeat PET-CT showed hypermetabolic activity around
the lung hila and aortic arch and in the right lung. Based
on the clinical findings, histopathology and after ruling
out other possible diseases, a diagnosis of mediastinal and
pleuropulmonary fibrosis was made.
In the year that followed, the patient was monitored biweekly.
Her prolactin level remained within normal range without
dopamine agonist treatment. She received immunosuppressive
therapy, prednisolone, methotrexate and mycophenolate
mofetil, as well as pulmonary hypertension treatment, sildenafil,
spironolactone and bumetanide. However, her symptoms
deteriorated despite radiological signs of disease regression.
She was hospitalized several times due to hemoptysis and
opportunistic infections. Endovascular stenting of the right
pulmonary artery was considered unsafe due to a high risk of
arterial rupture. Double lung transplantation was assessed to
be technically feasible and after much deliberation and detailed
discussions at multidisciplinary meetings, it was considered the
only option and the patient was admitted for the procedure.
Upon sternotomy, the right lung appeared fibrotic and atelectic.
It was adhered to the inner chest wall and appeared to be
receiving part of its blood supply from the chest wall. Sadly,
although the donor lungs were transplanted, the patient died on
the operating table due to uncontainable bleeding from the chest
wall and intercostal arteries.
DISCUSSION
We have presented an unusual complex case of pulmonary
hypertension. It remains unclear whether this is a case of
pulmonary hypertension complicating mediastinal fibrosis or
multi-organ affection with concurrent fibrotic changes in the
mediastinum, pulmonary artery, right lung, and pleura. It is
debatable whether there is an association with the ergot-derived
dopamine agonists, cabergoline and bromocriptine, that the
patient had received.
Pulmonary hypertension complicating mediastinal fibrosis
shares many similarities with proximal CTEPH including
perfusion defects on CTPA and V/Q scintigraphy (Seferian
et al., 2015), both of which have a high sensitivity for the
diagnosis of CTEPH (Galie et al., 2016). The most common
pattern of mediastinal fibrosis on CT is large, localized soft
tissue masses with or without calcifications, while diffuse
homogeneous soft tissue processes are less common (Sherrick
et al., 1994; Worrell et al., 2007). Hence, the lack of clear
radiological evidence of mediastinal masses, lymphadenopathy
and/or extrinsic compression and encasement of the pulmonary
arteries by neighboring tissues (Seferian et al., 2015) and the
nonspecific lung parenchymal affection in this patient led
to the incorrect diagnosis of CTEPH. Due to the variable
etiologies and clinical presentations, there is no standard
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FIGURE 1 | Pulmonary artery occlusion. CT pulmonary angiography (A)
showed near-complete occlusion of the right pulmonary artery without any
flow and elevated right hemidiaphragm. There was severe thickening of the left
lobar pulmonary arteries and short-segment stenosis (white triangles) and wall
irregularities (white arrow) in the left lobar and segmental pulmonary arteries.
Similar findings were observed during digital subtraction angiography (B).
therapy for mediastinal fibrosis. Pharmacology treatment is often
ineffective. However, there are reports of successful treatment
with corticosteroids and mycophenolate mofetil (Lal et al., 2005;
Ikeda et al., 2007; Witschi et al., 2009). Pulmonary hypertension
related to mediastinal fibrosis is associated with a poor
prognosis. Invasive interventions include endovascular stenting
and bypassing or reconstructing an obstructed pulmonary artery
(Brown et al., 2009; Seferian et al., 2015). In the current patient
case, as pharmacological treatment was unsuccessful and direct
manipulation of the right pulmonary artery was associated with a
high risk of artery rupture due to the extensive fibrotic changes,
lung transplantation was considered the only option. To the best
of our knowledge, this is the first described case of attempted
lung transplantation in a patient with mediastinal fibrosis, which,
regrettably, was unsuccessful.
Ergot-derived dopamine agonists, such as cabergoline,
pergolide and bromocriptine, can induce cardiac valve fibrosis
FIGURE 2 | Right pulmonary artery biopsy. Histologic examination
(hematoxylin and eosin stain) of the right pulmonary artery biopsy revealed
fibrotic connective tissue (A) infiltrated by inflammatory cells consisting of
lymphocytes and macrophages (B,C). Immunohistochemistry was carried out
for the leukocyte common antigen CD45 (D,E), immunoglobulin subclass
IgG4 (F,J) and a lymphocyte specific transcriptional factor: multiple MUM1
(H,I). Total magnification of 40× (A) and 400× (B–I).
and less frequently, non-cardiac fibrotic changes, such as
pleuropulmonary and retroperitoneal fibrosis, especially in
patients on long-term high-dose treatment for Parkinson’s
disease, usually a cumulative dose >2000 mg in the case of
cabergoline. The underlying mechanism is attributed to their
interaction with serotonin receptors (Schade et al., 2007;
Zanettini et al., 2007; Andersohn and Garbe, 2009). Low-dose
treatment for hyperprolactinemia is not associated with an
increased risk of clinically significant cardiac valvulopathy.
However, mild to moderate tricuspid regurgitation and
subclinical fibrotic lesions appear to be more prevalent during
cabergoline and bromocriptine treatment and pulmonary arterial
pressure, obtained on transthoracic echocardiography, was
reported to be higher, but within normal range, in patients
receiving bromocriptine (Elenkova et al., 2012; De Vecchis et al.,
2013).
Several previous case reports that suggest a possible link
between low-dose ergot-derived dopamine agonist treatment and
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clinically significant fibrotic changes are relevant to summarize
here. Severe mitral regurgitation caused by cabergoline therapy
(cumulative dose: ∼250 mg) was reported in a patient with
hyperprolactinemia (Cawood et al., 2009). After daily low-dose
cabergoline treatment (cumulative dose:∼180 mg), a patient with
acromegaly developed severe tricuspid regurgitation and dilated
right ventricle with impaired function (Izgi et al., 2010). In a
Parkinson patient, enlarged pulmonary artery, severe pulmonary
hypertension, pleural effusion and mediastinal lymphadenopathy
occurred after just one year of cabergoline treatment (cumulative
dose:∼730 mg) (Haro-Estarriol et al., 2009). Finally, constrictive
pericarditis was diagnosed in a hyperprolactinemia patient
treated with bromocriptine (cumulative dose: 14600 mg)
and cabergoline (cumulative dose: 320 mg) (Londahl et al.,
2008).These cases illustrate individual variations in susceptibility
to the fibrotic side effects of ergot-derived dopamine agonists.
Drug-induced pulmonary hypertension is well-recognized.
The best documented are the sympathomimetic anorexigens,
aminorex, benfluorex and other fenfluramine derivatives,
that have direct and indirect serotonergic effects (Seferian
et al., 2013). However, there is no clear evidence of a causal
relationship between ergot-derived dopamine agonists and
pulmonary hypertension. Pergolide and methyseride, both
of which are ergot-derivatives, are possibly associated with
pulmonary hypertension (Egermayer et al., 1999; Seferian et al.,
2013). Cabergoline and bromocriptine display agonist properties
at several serotonin receptors, including 5-HT1B, 5-HT2A,
and 5-HT2B (bromocriptine is a 5-HT2B antagonist, however)
(Newman-Tancredi et al., 2002), all of which are implicated in
the development of pulmonary hypertension. 5-HT1B receptors
mediate serotonin-induced pulmonary vasoconstriction and
vascular smooth muscle hypertrophy and hyperplasia, 5-HT2A
receptors induce pulmonary arterial adventitial fibroblast
proliferation and 5-HT2B receptors are involved in right
ventricular fibrosis (MacLean and Dempsie, 2010; Janssen et al.,
2015). Consistent with this, macroscopic and microscopic
structural changes were observed in the right pulmonary
artery of our patient suggesting that pulmonary hypertension
was caused by direct pulmonary artery affection possibly
in addition to extrinsic compression caused by mediastinal
fibrosis.
CONCLUDING REMARKS
It remains undetermined whether cabergoline and/or
bromocriptine treatment was the cause of mediastinal
fibrosis and pulmonary hypertension in this patient. Further
investigations are required to elucidate whether there is
an association between ergot-derived dopamine agonists
and mediastinal fibrosis and pulmonary hypertension.
In conclusion as CT and V/Q scintigraphy findings
can occasionally be deceptive, physicians should be
particularly aware of differential diagnoses in patients
without obvious history of venous thromboembolism that
are suspected of having chronic thromboembolic pulmonary
hypertension.
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